Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy

被引:32
|
作者
Trestini, Ilaria [1 ]
Carbognin, Luisa [1 ]
Sperduti, Isabella [2 ]
Bonaiuto, Clelia [1 ]
Auriemma, Alessandra [1 ]
Melisi, Davide [1 ]
Salvatore, Lisa [1 ]
Bria, Emilio [1 ]
Tortora, Giampaolo [1 ]
机构
[1] Univ Verona, Azienda Osped Univ Integrata, UOC Oncol, Verona, Italy
[2] Regina Elena Inst Canc Res, Dept Biostat, Rome, Italy
关键词
ENERGY-EXPENDITURE; CACHECTIC PATIENTS; CANCER CACHEXIA; MALNUTRITION; STRATEGIES; MANAGEMENT; OUTCOMES;
D O I
10.1038/s41430-018-0155-5
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background/objectives The aim of this analysis was to determine the risk of malnutrition and the prognostic value of nutritional intervention in patients affected by pancreatic ductal adenocarcinoma (PDAC) undergoing chemotherapy. Subjects/methods Clinical-pathological and nutritional data were correlated with overall survival (OS) using a Cox model. Nutritional status was determined by Malnutrition Universal Screening Tool (MUST), body mass index, weight loss in the past 6 months, presence of nutrition-related symptoms, and current energy intake. Nutritional intervention included appropriate individual dietary counseling. Results Data from 109 patients were gathered (median age 63 years). The majority of patients (64.2%) presented a MUST value of >= 2, corresponding to a high risk of malnutrition. At multivariate analysis for OS in locally advanced and metastatic PDAC patients, the time between the diagnosis and the nutritional intervention (HR 2.22, p = 0.017), the performance status (HR 1.38, p = 0.075), the surgery of the primary (HR 5.89, p = 0.005), and the response to the first line (HR 5.9, p = 0.03) were independent significant predictors of outcome. Furthermore, a weight gain > 2% from the baseline weight was correlated with the time between the diagnosis and the nutritional intervention (p = 0.021): in patients receiving a nutritional support within 3 months from diagnosis, a 2% weight gain was associated with a 2-year OS benefit (50.3% vs. 33.0%, p = 0.04). Conclusions This analysis suggests that the early nutritional support may contribute to influence the prognosis of patients affected by advanced PDAC undergoing chemotherapy.
引用
收藏
页码:772 / 779
页数:8
相关论文
共 50 条
  • [1] Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy
    Ilaria Trestini
    Luisa Carbognin
    Isabella Sperduti
    Clelia Bonaiuto
    Alessandra Auriemma
    Davide Melisi
    Lisa Salvatore
    Emilio Bria
    Giampaolo Tortora
    European Journal of Clinical Nutrition, 2018, 72 : 772 - 779
  • [2] Prognostic impact of nutritional support in patients affected by locally advanced or metastatic pancreatic cancer (PC) undergone chemotherapy
    Trestini, I.
    Carbognin, L.
    Bonaiuto, C.
    Auriemma, A.
    Melisi, D.
    Salvatore, L.
    Sperduti, I.
    Bria, E.
    Tortora, G.
    ANNALS OF ONCOLOGY, 2017, 28 : 53 - 53
  • [3] Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy
    Lindgaard, Sidsel C.
    Maag, Emil
    Sztupinszki, Zsofia
    Chen, Inna M.
    Johansen, Astrid Z.
    Jensen, Benny, V
    Bojesen, Stig E.
    Nielsen, Dorte L.
    Szallasi, Zoltan
    Johansen, Julia S.
    CANCERS, 2022, 14 (13)
  • [4] FOLFIRINOX for locally advanced and metastatic pancreatic ductal adenocarcinoma
    Hisai, Hiroyuki
    Tamaki, Sakurai
    Yuuki, Ikeda
    Yutaka, Koshiba
    Masafumi, Sato
    Ryosuke, Kawasaki
    Hiroshi, Gyobu
    Etsu, Miyazaki
    Tasuku, Hirako
    Shogo, Miura
    ANNALS OF ONCOLOGY, 2015, 26 : 120 - 120
  • [5] Prognostic impact of osteosarcopenia in patients undergoing pancreatic resection for pancreatic ductal adenocarcinoma
    Yanagaki, Mitsuru
    Onda, Shinji
    Gocho, Takeshi
    Igarashi, Yosuke
    Shirai, Yoshihiro
    Okui, Norimitsu
    Matsumoto, Michinori
    Sakamoto, Taro
    Haruki, Koichiro
    Ikegami, Toru
    LANGENBECKS ARCHIVES OF SURGERY, 2024, 409 (01)
  • [6] A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
    Wang, Yi
    Xiao, Xiuying
    Wang, Tianyi
    Li, Lin
    Zhu, Yue
    Xu, Haiyan
    Chu, Yuening
    Jiao, Feng
    Cui, Jiujie
    Wang, Liwei
    JOURNAL OF CANCER, 2018, 9 (07): : 1301 - 1307
  • [7] Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy
    Kim, Seung-seob
    Lee, Sunyoung
    Lee, Hee Seung
    Bang, Seungmin
    Park, Mi-Suk
    ABDOMINAL RADIOLOGY, 2021, 46 (02) : 655 - 666
  • [8] Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy
    Seung-seob Kim
    Sunyoung Lee
    Hee Seung Lee
    Seungmin Bang
    Mi-Suk Park
    Abdominal Radiology, 2021, 46 : 655 - 666
  • [9] Safety and efficacy of chemotherapy in older adults with locally advanced and metastatic pancreatic ductal adenocarcinoma (PDAC)
    Ostios-Garcia, Lorena
    Saade, Patricia
    Grossman, Joseph Elan
    Lanniello, Leanne
    Bullock, Andrea J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [10] Validation of Prognostic Radiomic Features From Resectable Pancreatic Ductal Adenocarcinoma in Patients With Advanced Disease Undergoing Chemotherapy
    Salinas-Miranda, Emmanuel
    Khalvati, Farzad
    Namdar, Kashayar
    Deniffel, Dominik
    Dong, Xin
    Abbas, Engy
    Wilson, Julie M.
    O'Kane, Grainne M.
    Knox, Jennifer
    Gallinger, Steven
    Haider, Masoom A.
    CANADIAN ASSOCIATION OF RADIOLOGISTS JOURNAL-JOURNAL DE L ASSOCIATION CANADIENNE DES RADIOLOGISTES, 2021, 72 (04): : 605 - 613